Renal Cell Carcinoma News and Research

Latest Renal Cell Carcinoma News and Research

Heavier and taller children have high risk of developing renal cell carcinoma as adults

A study of more than 300,000 individuals in Denmark, presented at this year's European Congress on Obesity in Glasgow, Scotland, reveals that heavier and taller children are at greater risk than their average-sized peers of developing renal cell carcinoma as adults.

29 Apr 2019

GARP protein can be a potential target for immunotherapy against colorectal cancer

Colorectal cancer is the third leading cause of cancer-related deaths in both men and women. Despite significant advances in therapies for this particular cancer, the five-year survival rate is 12 percent, according to the American Cancer Society.

19 Mar 2019

Overweight, obesity in adolescence associated with increased risk of renal cancer later in life

Being overweight has been linked with a higher risk of developing a form of kidney cancer called renal cell carcinoma among adults, but it's unclear if this risk is present during adolescence.

21 Feb 2019

Drug combinations could become first-line treatment for metastatic kidney cancer

A combination of two drugs - one of them an immunotherapy agent - could become a new standard, first-line treatment for patients with metastatic kidney cancer, says an investigator from Dana-Farber Cancer Institute, reporting results from a phase 3 clinical trial.

18 Feb 2019

Scientists propose quick and pain-free method for diagnosing kidney cancer

Sechenov University together with their German colleagues suggest a new highly sensitive, quick, and pain-free method for diagnosing kidney cancer.

21 Jan 2019

Obesity can be risk factor for developing renal cell carcinoma, confirms study

A new study confirms the long-suspected role of obesity as a risk factor for developing renal cell carcinoma, a type of kidney cancer, and identifies several specific obesity-related factors.

18 Jan 2019

MD Anderson Cancer Center and 4D pharma team up to evaluate live biotherapeutic oncology pipeline

The University of Texas MD Anderson Cancer Center and 4D pharma today announced a strategic collaboration to evaluate 4D's live biotherapeutic oncology pipeline across a range of cancer settings.

7 Jan 2019

Check your medical records for dangerous errors

When Liz Tidyman's elderly parents moved across the country to be closer to their children and grandchildren years ago, they carried their medical records with them in a couple of brown cardboard folders tied with string.

21 Nov 2018

Study identifies potential therapeutic strategy for patients with clear cell renal cancer

Researchers have provided new insight on the mechanisms behind the development of clear cell Renal Cell Carcinoma (ccRCC), according to new findings published in eLife.

13 Nov 2018

Patient Outcomes of Prostate Cancer with Whole Slide Imaging

An interview with Dr.

From Huron Digital Pathology 23 Oct 2018

FOTIVDA expected to be included in new ESMO guidelines for advanced renal cell carcinoma

EUSA Pharma welcomes the news that FOTIVDA (tivozanib) is expected to be included in the upcoming European Society of Medical Oncology clinical practice guidelines for advanced renal cell carcinoma, anticipated to be published at the end of this year.

22 Oct 2018

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

Study shows potential of avelumab plus axitinib as new treatment option for patients with advanced RCC

A combination of the immune checkpoint blocker, avelumab, plus the tyrosine kinase inhibitor, axitinib, significantly improves progression-free survival in previously untreated patients with advanced renal cell carcinoma in a phase 3 study, according to results presented at ESMO 2018 Congress.

22 Oct 2018

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Exelixis, Inc. today announced results from two analyses evaluating the effect of PD-L1 expression or prior treatment with immune checkpoint inhibitors on the efficacy of cabozantinib in patients with advanced renal cell carcinoma (RCC). The findings are being presented this week at the European Society for Medical Oncology 2018 Congress being held October 19-23 in Munich, Germany.

22 Oct 2018

X4 Pharmaceuticals announces clinical data of X4P-001-IO and Opdivo in patients with clear cell renal cell carcinoma

X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 antagonists to improve immune cell trafficking to treat cancer and rare disease, today announced results from a pilot study of X4P-001-IO in combination with Opdivo (nivolumab) in patients with clear cell renal cell carcinoma who are non-responsive to the anti-PD-1 checkpoint inhibitor Opdivo alone.

22 Oct 2018

New nanoplatform technology may reverse drug-resistance in renal cell carcinoma

A research team led by Arun Iyer, Ph.D., assistant professor of pharmaceutical sciences in the Eugene Applebaum College of Pharmacy and Health Sciences at Wayne State University, has developed a nanoplatform technology that works in combination with existing chemotherapeutic drugs that may reverse drug-resistance in renal cell carcinoma.

24 Sep 2018

China NMPA approves LENVIMA for treatment of unresectable hepatocellular carcinoma

Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth N.J., U.S.A., known as MSD outside of the United States and Canada, announced that the China National Medical Products Administration approved the kinase inhibitor LENVIMA (lenvatinib) as a single agent for the treatment of patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy.

24 Sep 2018

CHMP provides positive opinion to Cabometyx for previously-treated patients with hepatocellular carcinoma

Ipsen announced today that the Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines Agency, provided a positive opinion for Cabometyx (cabozantinib) as a monotherapy for the treatment of hepatocellular carcinoma in adults who have been previously treated with sorafenib.

21 Sep 2018

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma

Exelixis, Inc. today announced that its partner Ipsen Biopharmaceuticals Canada Inc. received approval from Health Canada of CABOMETYX® tablets for the treatment of adults with advanced renal cell carcinoma who have received prior vascular endothelial growth factor targeted therapy.

19 Sep 2018

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

Exelixis, Inc. today announced that the National Comprehensive Cancer Network updated its Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets.

7 Sep 2018

Renal Cell Carcinoma News and Research

Latest Renal Cell Carcinoma News and Research

Heavier and taller children have high risk of developing renal cell carcinoma as adults

GARP protein can be a potential target for immunotherapy against colorectal cancer

Overweight, obesity in adolescence associated with increased risk of renal cancer later in life

Drug combinations could become first-line treatment for metastatic kidney cancer

Scientists propose quick and pain-free method for diagnosing kidney cancer

Obesity can be risk factor for developing renal cell carcinoma, confirms study

MD Anderson Cancer Center and 4D pharma team up to evaluate live biotherapeutic oncology pipeline

Check your medical records for dangerous errors

Study identifies potential therapeutic strategy for patients with clear cell renal cancer

Patient Outcomes of Prostate Cancer with Whole Slide Imaging

FOTIVDA expected to be included in new ESMO guidelines for advanced renal cell carcinoma

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Study shows potential of avelumab plus axitinib as new treatment option for patients with advanced RCC

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

X4 Pharmaceuticals announces clinical data of X4P-001-IO and Opdivo in patients with clear cell renal cell carcinoma

New nanoplatform technology may reverse drug-resistance in renal cell carcinoma

China NMPA approves LENVIMA for treatment of unresectable hepatocellular carcinoma

CHMP provides positive opinion to Cabometyx for previously-treated patients with hepatocellular carcinoma

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Renal Cell Carcinoma News and Research

Latest Renal Cell Carcinoma News and Research

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in